720
Views
32
CrossRef citations to date
0
Altmetric
Clinical trials

A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis

, , , &
Pages 574-581 | Received 06 May 2013, Accepted 30 Jun 2013, Published online: 19 Aug 2013
 

Abstract

Tirasemtiv is a fast skeletal muscle activator that increases the sensitivity of the sarcomere to calcium, increasing the efficiency of muscle contraction when the muscle is stimulated at submaximal contraction frequencies. A previous study showed single doses of tirasemtiv to be well tolerated and associated with potentially important improvements in a variety of functional outcomes. This study determined safety of tirasemtiv when given at doses up to 500 mg daily for three weeks. Tirasemtiv was given as a single daily dose up to 375 mg for two weeks, with and without concomitant riluzole. In a separate cohort, an ascending dose protocol evaluated a total dose of 500 mg daily given in two divided doses. Safety and tolerability were assessed, as well as measures of function, muscle strength and endurance. Results showed that tirasemtiv was well tolerated, with dizziness the most common adverse event. Tirasemtiv approximately doubled the serum concentration of riluzole. Trends were noted for improvement in ALSFRS-R, Maximum Minute Ventilation, and Nasal Inspiratory Pressure. In conclusion, tirasemtiv is well tolerated and can be given safely with a reduced dose of riluzole. Positive trends in multiple exploratory outcome measures support the further study of this agent in ALS.

NEALS/Cytokinetics Study Team

Mary Lou Watson, Deborah Bradshaw, Upstate Medical University, Syracuse, NY; Richard Barohn, University of Kansas, Kansas City, KS; Kevin Boylan, Mayo Clinic, Jacksonville, FL; Benjamin Brooks, Carolinas Medical Center, Charlotte, NC; Terry Heiman-Patterson, Drexel University, Philadelphia, PA; Jonathan Katz, California Pacific Medical Center, San Francisco, CA; Nicholas Maragakis, Johns Hopkins University, Baltimore, MD; Hiroshi Mitsumoto, Columbia University, New York, NY; Zachary Simmons, Penn State University, Hershey, PA; Richard Bedlack, Duke University, Durham, NC; James Berry, Massachusetts General Hospital, Boston, MA; Kimberly Goslin, Providence ALS Center, Portland, OR; Carlayne Jackson, University of Texas, San Antonio, TX; John Kissel, Ohio State University, Columbus Ohio: Dale Lange, Hospital for Special Surgery, New York, NY; Jonathan Licht, Coordinated Clinical Research, La Jolla, CA; Tahseen Mozaffar, University of California, Irvine, CA; Kara Burroughs, Karen Calloway, Jesse Cedarbaum, Michael M. Chen, Garrett Collins, Erin Donnelly, Bradley Fugate, Jacqueline Lee, Jean Masonek, Mark O’Neill, Joe Serooge, Jun Zhang, Cytokinetics, Inc.

Declaration of interest: J. Shefner has received consulting income from Cytokinetics. L. Meng and A. A. Wolff are employees. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.